Hi-Tech acquires Mag-Ox line from Blaine
AMITYVILLE, N.Y. Hi-Tech Pharmacal on Tuesday announced the signing of an acquisition agreement for the Mag-Ox line of Magnesium Nutritional supplements from Blaine Co. in a transaction valued at $4.1 million.
Under the terms of the acquisition Hi-Tech receives rights to the Mag-Ox, Maginex, Uro-Mag and Corban brands. The products had net sales of approximately $3.4 million in calendar 2009.
“The acquisition of these magnesium brands is a good strategic fit for [Hi-Tech’s] diabetic line since magnesium is a common nutritional deficiency among people with diabetes as well as those with metabolic syndrome, high blood pressure and cardiovascular conditions,” stated David Seltzer, Hi-Tech president and CEO.
NFL coach to pitch Extenze
MONROVIA, Calif. —Can two-time Super Bowl coach Jimmy Johnson do for the supplement male enhancement category what Bob Dole did for Viagra?
That’s exactly what Biotab Nutraceuticals and its agency InterQuantum are hoping—legitimizing a supplement category that often provides the punch line for late night comics. The company signed Johnson in January to represent its Extenze male enhancement product. Biotab plans to pitch the pitchman pretty heavily to American consumers throughout the year with an overall marketing budget of $70 million.
With Extenze now sold at retail, the product scored No. 1 in sales in the mineral supplement category at mass retailers for the last quarter of 2009, InterQuantum added, citing InfoScan Reviews. Mineral supplement sales currently are up 3% to $544.5 million for the 52 weeks ended Dec. 26 across food, drug and mass outlets, according to Nielsen Group data.
CDC panel expands influenza vaccination recommendations
ATLANTA A panel of immunization experts reporting to the Centers for Disease Control and Prevention on Wednesday voted to expand the recommendation for annual influenza vaccination to include all people ages 6 months and older, a marked change from recommendations in the past that identified high-priority groups by age and condition, groups that apply to approximately 85% of the population.
The expanded recommendation is to take effect in the 2010/2011 influenza season. The new recommendation seeks to remove barriers to influenza immunization and signals the importance of preventing influenza across the entire population, the agency stated.
Discussion at the ACIP meeting focused on the value of protecting all people 19 to 49 years of age, who have been hard hit by the 2009 H1N1 pandemic virus, which is likely to continue circulating into next season and beyond. Another reason cited in favor of a universal recommendation for vaccination is that many people in currently recommended “higher risk” groups are unaware of their risk factor or that they are recommended for vaccination.
Finally, new data collected over the course of the 2009 H1N1 pandemic indicates that some people who do not currently have a specific recommendation for vaccination also may be at higher risk of serious flu-related complications, including those people who are obese, post-partum women and people in certain racial/ethnic groups.
More influenza vaccine doses will be required to vaccinate all adults. However, based on current projections, more licensed types and brands of seasonal influenza vaccines will be available in the 2010-11 influenza season than has ever been available before.
Historically, uptake of seasonal influenza vaccine has been less than half of the number of persons with a specific recommendation for vaccination.